Welcome to our dedicated page for Inmune Bio news (Ticker: INMB), a resource for investors and traders seeking the latest updates and insights on Inmune Bio stock.
INmune Bio Inc. develops clinical-stage immunology and biotechnology treatments designed to target the innate immune system in disease. Company news commonly centers on three platforms: CORDStrom, a pooled allogeneic human umbilical cord-derived mesenchymal stromal/stem cell platform; XPro, a dominant-negative TNF platform intended to selectively neutralize soluble TNF; and INKmune, a cell-based medicine designed to prime natural killer cells against residual cancer.
Recurring updates include clinical and preclinical data, regulatory pathway discussions, manufacturing and collaboration agreements, conference presentations, shareholder communications, and quarterly or annual financial results. Coverage also reflects program areas such as recessive dystrophic epidermolysis bullosa, early Alzheimer’s disease, neuroinflammation, inflammatory disease and oncology.
INmune Bio (NASDAQ: INMB) reported Q1 2026 results and operational milestones on May 7, 2026. Key highlights: net loss $5.4M, R&D $3.6M, G&A $2.2M, and ~26.6M shares outstanding as of May 7, 2026.
Clinical progress: CORDStrom MAA to the UK MHRA mid-summer, follow-on EMA and planned FDA BLA in Q4 2026; XPro advanced to adaptive Phase 2b/3 for early Alzheimer’s; ongoing imaging analyses and preclinical INB03 data reported.
INmune Bio (NASDAQ: INMB) and Anthony Nolan signed an amended and restated Material Transfer and License Agreement effective April 29, 2026 to expand long‑term supply of umbilical cord tissue for the CORDStrom™ MSC platform.
The collaboration targets Recessive Dystrophic Epidermolysis Bullosa (RDEB), oncology (CORDStrom‑TRAIL), osteoarthritis, and systemic lupus erythematosus, and includes GMP, HTA traceability, and global regulatory compliance provisions.
American Biotech Innovation Alliance (ABIA) launched on May 5, 2026, with 21 founding member companies to develop a national biotech innovation strategy addressing regulatory policy, capital formation, manufacturing, and workforce development.
ABIA will convene leaders across U.S. regions to produce a flagship report and actionable recommendations for policymakers and industry stakeholders.
INmune Bio (NASDAQ: INMB) will report first-quarter 2026 results and host a corporate update via conference call and webcast on May 7, 2026 at 4:30 PM ET. Management will discuss the quarter ended March 31, 2026; a transcript and replay will be available after the call.
Dial-in numbers, conference ID INMUNE, and a live webcast link are provided; the replay is available through May 21, 2026.
INmune Bio (NASDAQ: INMB) reported preclinical AACR 2026 data showing that INB03 (XPro1595), a dominant-negative soluble TNF inhibitor, enhanced the anti-tumor activity of TKIs lapatinib and tucatinib and reduced metastases in HER2-positive breast cancer models.
Key findings include statistically superior inhibition of cell proliferation and migration (p < 0.05 to p < 0.0001), slowed tumor growth in mouse models, and reduced brain, lung, and liver metastases; poster available April 21, 2026.
INmune Bio (NASDAQ: INMB) reported 2025 results and a business update on March 30, 2026. Key items: CORDStrom MAA filing to the UK MHRA mid-summer 2026 with subsequent EMA and expected U.S. BLA in Q4 2026, completed three pilot commercial manufacturing runs, and FDA alignment for an adaptive Phase 2b/3 pathway for XPro in early Alzheimer’s.
Financials: net loss $45.9M, R&D $20.7M, impairment $16.5M, cash $24.8M and runway through Q1 2027; sold 4.30M shares for $27.5M net.
INmune Bio (NASDAQ: INMB) will report year-ended December 31, 2025 financial results and provide a corporate update on Monday, March 30, 2026 at 4:30 PM Eastern Time. Management will host a conference call and live audio webcast; replay available through April 13, 2026.
Dial-in numbers, conference ID, webcast link, and replay details were provided for investor access.
INmune Bio (NASDAQ: INMB) announced that its Phase 2 MINDFuL trial of XPro1595 (pegipanermin) was highlighted in a plenary at AD/PD 2026 as an example of matching inflammatory biomarker enrichment to mechanism of action.
The company reports that MINDFuL showed consistent efficacy signals in an inflamed patient subgroup and that INmune Bio has FDA alignment to advance an integrated Phase 2b/3 registrational program for biomarker‑enriched early Alzheimer’s patients.
INmune Bio (NASDAQ: INMB) will host a webinar on February 27, 2026 at 9:30 a.m. ET to discuss the registrational pathway for XPro1595 in early Alzheimer’s disease with inflammation biomarkers.
Speakers will review Phase 2 MINDFuL results, FDA End‑of‑Phase 2 feedback supporting a biomarker‑enriched registrational study design, and the Company's Phase 3 roadmap including plans to pursue global partnerships. Registration link is provided for investors and clinicians.
INmune Bio (NASDAQ: INMB) will host a webinar on February 26, 2026 at 1:00 p.m. ET to present new clinical data for CORDStrom™ in recessive dystrophic epidermolysis bullosa (RDEB).
Presentations will highlight MissionEB Phase III results including EBDASI skin score improvements versus placebo, pediatric weight gain, reductions in pain and itch, and enhanced daily functioning as reported by principal investigators.